“OneVentures have been terrific to work with as a lead investor, but it’s what they add in addition to investment that has been critical to Vaxxas’ growth. Their biotech team comes from leadership roles with hands-on industry experience spanning technology to business development. Vaxxas is tremendously fortunate – working with the OneVentures team has translated into sharpening all aspects of our development and commercialisation strategy, and actively helped us forge connections and partners with industry. I cannot recommend them highly enough.”

“I first met the OneVentures team in July 2018. They quickly impressed me with their broad knowledge and capabilities. Shortly afterwards, they led our Series C round. It has been a pleasure to build the company with the support of Paul, Sarah, Michelle, and Gabriel, and their LP’s over the past 3 years. The fund is a true value add investor with deep connections to academic institutions and opinion leaders.”

“The 1V team have been part of the journey since our inception – from pitching at WestFest in 2016 and Michelle handing out an investors award, to participating in our Series A it’s been a great vote of confidence having the team on the cap table. Nick has been a great addition as a shadow board advisor and has been able to bring his vast experience in scaling European companies to Australia. Being part of the 1V family has opened opportunities across the Australian investor community and their commitment to helping founders grow has been unparalleled – not only from a learning & development perspective, but also connecting founders together in various stages of growth.”

“OneVentures are a unique, one of a kind investor in the venture capital world. They put tremendous faith in their portfolio companys’ teams to deliver results, and are always on hand to provide pointed advice or step in to fill organizational gaps. BiVACOR has fortunately been part of the OneVentures family for nearly 4 years now, and their unyielding support has allowed our organization to pursue our dream of developing a practical replacement to the failing human heart. Without the OneVentures team, we would not be where we are today!”

“Working with OneVentures and their partners Viola Credit to secure venture credit funding to support our Series A round was a pleasure – Nick and the team were great to work with and the process was rigorous but fast. They’ve been valuable partners in providing ongoing support and advice as we continue to scale, and their partnership with Viola in Israel added a combined level of expertise and capability which was attractive for us as we expand internationally.”

“Before our commencement with OneVentures, their engagement, efficiency, and honesty during our cap raise process were real differentiators for us. As part of our due diligence process, each interaction showed us that they would be equitable and fair – exactly the kind of partner we were looking for.

During our initial board meetings and engagement sessions, we appreciated that they took the time to truly understand our business and how we operate. They were respectful and considerate as they got to know our team and their roles along with our board members and existing investors.

As OneVentures have supported us to take Lumary to the next level, their consultation and input across many parts of the business has been excellent. In particular, Grant’s integration and insight into crucial metrics and deliberate tracking was invaluable while Nigel brought significant support where we needed it most as we matured the operation of our business.

OneVentures passion for healthcare and their role as a venture capital partner is incredibly balanced. They are a true reflection of a partner who wants to do good while considering all aspects.”